|Day Low/High||0.63 / 0.65|
|52 Wk Low/High||0.11 / 1.61|
New details were released Tuesday from the phase III study of Celgene's Abraxane in pancreatic cancer.
Expanding use of Abraxane into pancreatic cancer could net Celgene another $1 billion in revenue.
Celgene's Abraxane delays tumor growth in patients with advanced melanoma.
A study of Abraxane in pancreatic cancer generates a ton of buzz even with data still weeks away.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.